22nd Century Group, Inc. (XXII) - Long-Term Debt to Capital

Efficient raw material supply chains for low-nicotine products ensure stability for 22nd Century Group (XXII). Its status as a healthcare innovator and the trust of regulatory bodies strengthen the brand's position. The price action on GURU.Markets confirms the potential of the company, which is creating a monopoly market through FDA patents, while the separate_debt_long_eq metric stands at 0.05, contributing to the growth of free cash flow.

The development of 22nd Century Group (XXII) requires capital-intensive plantation management and the protection of genetic patents. This long-term debt-to-equity ratio digitizes the balance between borrowed funds and shareholder value. The metric measures the company's ability to service obligations exceeding one year without the risk of default. An increase in this value signals an excessive credit load. The long-term debt-to-equity ratio trend reveals the efficiency of financial leverage.